

Protalix BioTherapeutics, Inc.
Form 8-K
February 05, 2010

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): February 5, 2010 (February 4, 2010)

**Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)**

**Florida
(State or other jurisdiction
of incorporation)**

**000-33357
(Commission File Number)**

**65-0643773
(IRS Employer
Identification No.)**

**2 Snunit Street
Science Park, POB 455
Carmiel, Israel
(Address of principal executive offices)**

**20100
(Zip Code)**

**Registrant's telephone number, including area code +972-4-988-9488
(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

On February 4, 2010, Protalix BioTherapeutics, Inc. (the Company) issued a press release announcing that data from its pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease will be presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010, February 10 through 12, 2010 in Miami, Florida. Hanna Rosenbaum, M.D., Director of Hematology Day Care Unit, RAMBAM Medical Center, Haifa, Israel, and study investigator, will give the oral presentation, titled: Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa, on Thursday, February 11, 2010, at 10:15 AM ET. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

99.1 Press release dated February 4, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROTALIX BIOTHERAPEUTICS, INC.

Date: February 5, 2010

By: /s/ David Aviezer

Name: David Aviezer, Ph.D.

Title: President and Chief Executive
Officer

3